Dr. Tzachanis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3855 Health Sciences Drive
MC 0960
La Jolla, CA 92093Phone+1 858-822-6600Fax+1 858-822-6844
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2000 - 2003
Aristotle University of Thessaloniki School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2012 - 2026
MA State Medical License 2003 - 2018- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation Start of enrollment: 2019 Nov 26
Publications & Presentations
PubMed
- 129 citationsLenalidomide enhances anti-myeloma cellular immunityKatarina Luptakova, Jacalyn Rosenblatt, Brett Glotzbecker, Heidi Mills, Dina Stroopinsky
Cancer Immunology, Immunotherapy. 2013-01-01 - 24 citationsPatient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson
Blood. 2022-11-24 - 815 citationsInterleukin-2 and Regulatory T Cells in Graft-versus-Host DiseaseJohn Koreth, Ken-ichi Matsuoka, Haesook T. Kim, Sean McDonough, Bhavjot Bindra
The New England Journal of Medicine. 2011-11-30
Abstracts/Posters
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...Dimitrios Tzachanis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell TherapyJune 3rd, 2021
Dr. Tzachanis on Data with Lisocabtagene Maraleucel in LymphomaFebruary 28th, 2020
Cancer Cell Therapy Success Grows, but Hospitals Struggle with CostOctober 4th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
